Clinical trials: Radiographic Contrast Agent Nephropathy
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Contrast-induced Nephropathy, Coronary Angiography
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
This study is designed to compare the bioavailability of the test Product(CE-Iohexol Injection) and the reference product Iohexol Injection (Omnipaque™) following intravenous injection in normal healthy volunteers.
- Trial name
- NCT03869983
- Testing
- Omnipaque™ (iohexol) Injection, CE-Iohexol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CyDex Pharmaceuticals, Inc.
Radiographic Contrast Agent Nephropathy
Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System
The investigators hypothesize that a Clinical Decision Support System (CDSS) designed with "Patient-Specific" reminders yields superior performance than that with "Non-patient-specific" reminders in preventing contrast-induced…
- Trial name
- NCT01778140
- Testing
- Patient-specific computerized reminder, Non-patient-specific computerized reminder
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University